Impact of anti-CD20 monoclonal antibodies on serologic response to
Por um escritor misterioso
Descrição
Progress with the use of monoclonal antibodies for the treatment of systemic lupus erythematosus
Imaging the mechanisms of anti-CD20 therapy in vivo uncovers spatiotemporal bottlenecks in antibody-dependent phagocytosis
Neutralizing antibody against anti–SARS-CoV-2 vaccination
Rituximab for the treatment of multiple sclerosis: a review
Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma
Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies
Tumor-reactive antibodies evolve from non-binding and autoreactive precursors - ScienceDirect
Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response - ScienceDirect
Mechanisms of killing by anti-CD20 monoclonal antibodies - ScienceDirect
Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin's lymphomas
Neutralizing antibody against anti–SARS-CoV-2 vaccination
Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti–SARS-CoV-2 Antibodies
/s.glbimg.com/po/tt2/f/original/2013/04/19/f6.jpg)
